|
| related topics |
| {product, liability, claim} |
| {product, market, service} |
| {condition, economic, financial} |
| {customer, product, revenue} |
| {stock, price, share} |
| {personnel, key, retain} |
| {stock, price, operating} |
| {system, service, information} |
|
|
Company Background and Evolution True Collaboration versus Videoconferencing
Recent adverse economic and market conditions may result in further budgetary constraints within the defense and intelligence communities, as well as a downturn in spending on real-time collaboration solutions by other users, that could adversely affect our revenues and results of operations.
We may be unable to return to profitability
A significant portion of our revenue is attributable to a small number of major customers,
none of whom is obligated to continue to use our products and services.
The continued redirection of budget funds and increased competition within our Department of Defense customer base would negatively impact our results of operations and financial condition.
Loss of access to certain third-party technology utilized in our products could materially harm our business.
Our success depends upon market acceptance of our collaboration products.
If we are unable to adapt to the rapid pace of change in our market, our business could be adversely affected.
Our results of operations would suffer if we are unable to effectively compete in the market for multimedia collaboration products.
If we release products containing defects or experience delays in releasing new products, our competitive position could be adversely effected.
The loss of or failure to retain or attract talented directors, officers and personnel could harm our business.
The trading price of our common stock may continue to be volatile, which may adversely affect our business, and investors in our common stock may experience substantial losses.
Our common stock is traded on the OTC Bulletin Board, making it a less liquid investment than if it were traded on a national securities exchange.
Full 10-K form ▸
|
|
| related documents |
| 943894--3/31/2010--EZENIA_INC |
| 943894--3/28/2008--EZENIA_INC |
| 1033905--3/16/2006--LUMINEX_CORP |
| 1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 874734--3/8/2010--OSTEOTECH_INC |
| 1270597--3/23/2007--MERISANT_CO |
| 8146--4/9/2010--ASTRO_MED_INC_/NEW/ |
| 780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 768408--6/24/2010--CYANOTECH_CORP |
| 65759--2/17/2010--MICROPAC_INDUSTRIES_INC |
| 739944--3/10/2009--MEDTOX_SCIENTIFIC_INC |
| 1006045--3/30/2007--IRIDEX_CORP |
| 31791--2/26/2009--PERKINELMER_INC |
| 882873--9/21/2009--UROLOGIX_INC |
| 739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
| 739944--3/15/2007--MEDTOX_SCIENTIFIC_INC |
| 739944--3/17/2006--MEDTOX_SCIENTIFIC_INC |
| 1324759--3/31/2010--Cereplast_Inc |
| 1025573--4/2/2007--NATROL_INC |
| 941604--2/27/2006--COINSTAR_INC |
| 10795--11/24/2010--BECTON_DICKINSON_&_CO |
| 827156--10/15/2007--ZILA_INC |
| 880432--9/28/2009--MISONIX_INC |
| 8063--3/11/2009--ASTRONICS_CORP |
| 25895--6/28/2010--CROWN_CRAFTS_INC |
| 1013606--2/29/2008--ENDOLOGIX_INC_/DE/ |
| 874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE |
| 1050007--11/20/2008--NUTRACEUTICAL_INTERNATIONAL_CORP |
|